362 related articles for article (PubMed ID: 18483253)
1. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
2. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
Puca R; Nardinocchi L; Bossi G; Sacchi A; Rechavi G; Givol D; D'Orazi G
Exp Cell Res; 2009 Jan; 315(1):67-75. PubMed ID: 18996371
[TBL] [Abstract][Full Text] [Related]
3. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
5. HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA.
Nardinocchi L; Puca R; Sacchi A; D'Orazi G
Biochem Biophys Res Commun; 2007 Sep; 361(1):249-55. PubMed ID: 17658469
[TBL] [Abstract][Full Text] [Related]
6. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation.
Rui Y; Xu Z; Lin S; Li Q; Rui H; Luo W; Zhou HM; Cheung PY; Wu Z; Ye Z; Li P; Han J; Lin SC
EMBO J; 2004 Nov; 23(23):4583-94. PubMed ID: 15526030
[TBL] [Abstract][Full Text] [Related]
7. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
8. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
Puca R; Nardinocchi L; Givol D; D'Orazi G
Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.
Li XL; Arai Y; Harada H; Shima Y; Yoshida H; Rokudai S; Aikawa Y; Kimura A; Kitabayashi I
Oncogene; 2007 Nov; 26(51):7231-9. PubMed ID: 17533375
[TBL] [Abstract][Full Text] [Related]
10. Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression.
Möller A; Sirma H; Hofmann TG; Staege H; Gresko E; Lüdi KS; Klimczak E; Dröge W; Will H; Schmitz ML
Oncogene; 2003 Nov; 22(54):8731-7. PubMed ID: 14647468
[TBL] [Abstract][Full Text] [Related]
11. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
[TBL] [Abstract][Full Text] [Related]
12. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH
Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570
[TBL] [Abstract][Full Text] [Related]
13. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
14. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model.
Nambiar PR; Giardina C; Guda K; Aizu W; Raja R; Rosenberg DW
Cancer Res; 2002 Jul; 62(13):3667-74. PubMed ID: 12097273
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
D'Orazi G; Garufi A; Cirone M
IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
[TBL] [Abstract][Full Text] [Related]
16. FHL2 mediates p53-induced transcriptional activation through a direct association with HIPK2.
Lee SW; Kim EJ; Um SJ
Biochem Biophys Res Commun; 2006 Jan; 339(4):1056-62. PubMed ID: 16343438
[TBL] [Abstract][Full Text] [Related]
17. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
[TBL] [Abstract][Full Text] [Related]
18. The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4.
Yamada D; Pérez-Torrado R; Filion G; Caly M; Jammart B; Devignot V; Sasai N; Ravassard P; Mallet J; Sastre-Garau X; Schmitz ML; Defossez PA
Oncogene; 2009 Jul; 28(27):2535-44. PubMed ID: 19448668
[TBL] [Abstract][Full Text] [Related]
19. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
D'Orazi G; Sciulli MG; Di Stefano V; Riccioni S; Frattini M; Falcioni R; Bertario L; Sacchi A; Patrignani P
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):735-41. PubMed ID: 16467083
[TBL] [Abstract][Full Text] [Related]
20. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein.
Vinyals A; Peinado MA; Gonzalez-Garrigues M; Monzó M; Bonfil RD; Fabra A
Gene Ther; 1999 Jan; 6(1):22-33. PubMed ID: 10341872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
